Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601)

John M S Bartlett, Alison F Munro, Janet A Dunn, Christopher McConkey, Sarah Jordan, Chris J Twelves, David A Cameron, Jeremy Thomas, Fiona M Campbell, Daniel W Rea, Elena Provenzano, Carlos Caldas, Paul Pharoah, Louise Hiller, Helena Earl, Christopher J Poole

Research output: Contribution to journalArticlepeer-review

Abstract

The NEAT/BR9601 trial showed benefit for addition of anthracyclines to cyclophosphamide, methotrexate, and fluorouracil (CMF) as adjuvant treatment for early breast cancer. We investigated prospectively predictive biomarkers of anthracycline benefit including HER2 and TOP2A.
Original languageEnglish
Pages (from-to)266-74
Number of pages9
JournalThe Lancet Oncology
Volume11
Issue number3
DOIs
Publication statusPublished - 2010

Keywords

  • Antibiotics, Antineoplastic
  • Antigens, Neoplasm
  • Antineoplastic Combined Chemotherapy Protocols
  • Biomarkers, Pharmacological
  • Breast Neoplasms
  • DNA Topoisomerases, Type II
  • DNA-Binding Proteins
  • Disease-Free Survival
  • Epirubicin
  • Female
  • Gene Amplification
  • Genes, erbB-2
  • Humans
  • Immunohistochemistry
  • Middle Aged
  • Multivariate Analysis
  • Oligonucleotide Array Sequence Analysis
  • Patient Selection
  • Predictive Value of Tests
  • Prospective Studies
  • Survival Analysis
  • Tumor Cells, Cultured

Fingerprint

Dive into the research topics of 'Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601)'. Together they form a unique fingerprint.

Cite this